The Lifting Of The Ban Storm Hit The Stock Price Was Down, Germany Exhibition Health Frequent Acquisitions Busy Transformation

A securities practitioner told reporters that the lifting of restrictions on restricted shares would have a greater impact on the company's share price. One is to see whether the lifting of the ban is huge. Second, whether shareholders have cash demand and whether they have confidence in the development of the company is also an influencing factor.

Although the controlling shareholder publicly stated that there was no reduction plan, but in the disclosure of more than 900 million shares will be lifted the next day, restricted sale can be listed circulation, in November 18th, Germany exhibition health (000813) share price is still broken down.

Not only the share price is under pressure, but also the performance pressure after the implementation of "collecting and expanding the surface". In this regard, this year's internal health exhibition launched several acquisitions. On the evening of 19 th, the German exhibition Health announced the acquisition of hemp investment shares and further marching into the industrial hemp business.

Massive lifting of stock price limit

Recently, the lifting of restrictions on restricted shares has become a "thunder" for investors to avoid it.

On the evening of the 17 th of this month, the German exhibition health bulletin said that in November 19th, the company will have about 933 million shares of restricted shares lifted, accounting for 41.64% of the company's share capital. According to the 18 day closing price of Germany exhibition health, the market value of the lifted shares is about 6 billion 800 million yuan.

The object of the lifting of the ban is mainly Merrill Lynch holdings, Shanghai Yue Ye, Tibet Jin Tong, Shenzhen Mount Everest cornerstone and other shareholders, of which Merrill Lynch holdings is the largest shareholder of Germany exhibition health, holding 24.72% of the total share capital of the company.

It seems that in order to stabilize investor sentiment, the German exhibition health is also emphasized in the aforementioned announcement that the restricted sale of shares will be released after the sale is restricted, and Merrill Lynch will apply for the settlement limit according to the deadline of the deadline. Merrill Lynch Holdings has no reduction plan for the time being. In the future, if there is a need for capital reduction, it will disclose the reduction plan according to the provisions, mainly reducing the shares by way of agreement transfer.

However, the lifting of the ban on the sale of shares has caused a greater response in the two tier market. In November 18th, the health price of Germany exhibition was lower and lower. At 10:49 a.m., it was closed until the close. The stock price closed at 7.27 yuan / share.

Today (November 20th), German exhibition health shares again opened lower, the closing price of 6.89 yuan / share, down 3.23%.

A securities practitioner told reporters that the lifting of restrictions on restricted shares would have a greater impact on the company's share price. One is to see whether the lifting of the ban is huge. The two is to see whether shareholders have cash demand and confidence in the development of the company.

From the perspective of German exhibition health, although it said in the announcement, Merrill Lynch Holdings has no reduction plan. However, a notice released on the 7 th day of Dezhou health showed that Merrill Lynch had postponed the repurchase of some of its pledge shares. Germany exhibition Health said, Merrill Lynch holdings in accordance with the original plan to reduce leverage and reduce the rate of pledge, to return the pledge loan, after the drop leverage plan is still in the process of implementation, funds are not yet fully in place, affecting the repayment of the loan on schedule.

The announcement revealed that Merrill Lynch currently has a total loan balance of 3 billion 895 million yuan, and the amount of debt to be paid in the next six months and within one year is 3 billion 710 million yuan, and the asset liability ratio is 56.98%. Although the German Health Exhibition said that Merrill Lynch's overall asset liability ratio remained within the normal range, it planned to reduce the overall pledge ratio by issuing exchangeable bonds and expanding other financing channels. But at present, Merrill Lynch has pledged 99.99% of its German health shares, accounting for 33.24% of the total health share of Germany exhibition.

Under the pressure of high pledge rate, higher asset liability ratio and pledge extension period, whether the Merrill Lynch holdings will follow the reduction to meet the needs of capital is unknown.

Extension of industrial hemp layout

On the one hand, share price pressure, on the other hand, Germany exhibition health performance is also facing greater pressure. As a listed company whose original business is textile, German exhibition health in 2016 through the major asset reorganization will Jialin pharmaceutical revenue capsule, into the pharmaceutical industry in one fell swoop. Jialin pharmaceutical is mainly engaged in the research, production and sales of cardiovascular and cerebrovascular drugs, and its core product is atorvastatin calcium - "ah le".

In September this year, in the new round of "collecting and expanding the surface", "ah le" was eliminated. This means that in Shanxi, Jiangsu, Jilin and other 25 regional markets, "ah le" will be difficult to compete with the winning products. It is noteworthy that, according to previous performance calculations, "ah le" products accounted for more than 95% of the German exhibition's healthy revenue. This time, it was eliminated in the "expansion of mining and expanding", and the company's performance or impact was not small.

Perhaps it is the risk of "one drug" supporting performance. This year, the German development company frequently relies on acquisitions to expand its business, and there are many premium acquisitions.

In March this year, the German Health Exhibition proposed a price of 400 million yuan to buy 25% stake in hemp investment. After the agreement is reached, the two sides will carry out deep cooperation on the health industry of cannabis.

In September 24th, German exhibition Health announced that it signed investment letter of intent with Beijing Changjiang Mai Pharmaceutical Technology Co., Ltd. and its major shareholder Dai Yan, and will enter the field of disinfection technology to expand its product line and open up new profit growth points.

In September 27th, the German exhibition was a healthy and premium purchase of 25.05% stake in Shandong Jincheng medicine. Insiders told the media that the exhibition was healthy, and this time it looked at the oligopoly position of Jincheng medicine in the field of cephalosporin intermediate.

In October, the German exhibition health bulletin was proposed to increase capital to Beijing Oriental bio pharmaceutical Polytron Technologies Inc by 300 million yuan in Monetary Fund. For the purpose of increasing capital, Dezhou Health said in its announcement that the company, with its existing products in clinical research and development (including phase two and phase three approved before the listing), and the introduction of innovative drugs at home and abroad, and the investment cooperation of high-quality pharmaceutical companies, needs funds from the introduction of investors, the development of health to enrich its own product lines and expand the market, and intends to participate in the above-mentioned projects of the company, and intends to cooperate with them.

On the 19 th of this month, German exhibition Health announced that the company signed an agreement with Han Zhong Group and hemp investment to acquire 20% stake in hemp bio products held by hemp investment, and the transaction price was 100 million yuan. German health shows that as the source of the industrial hemp industry chain, Su Ma biological industry is the core node of the industrial hemp industry chain. This foreign investment intends to further implement the company's development strategy, layout industrial hemp seed cultivation and planting business, so as to achieve stable source of raw materials in the field of industrial hemp application.

The layout of cannabis seeds is another extension of the German Health Exhibition in the field of industrial hemp after the layout of cannabis drugs and hemp products this year. On the afternoon of 20, the reporter called the health exhibition manager of the German exhibition, but at the time of the press release, the phone was not answered.